% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Honda:137681,
author = {K. Honda and V. Katzke$^*$ and A. Hüsing$^*$ and S. Okaya
and H. Shoji and K. Onidani and A. Olsen and A. Tjønneland
and K. Overvad and E. Weiderpass and P. Vineis and D. Muller
and K. K. Tsilidis and D. Palli and V. Pala and R. Tumino
and A. Naccarati and S. Panico and K. Aleksandrova and H.
Boeing and H. B. Bueno-de-Mesquita and P. H. Peeters and A.
Trichopoulou and P. Lagiou and K.-T. Khaw and N. J. Wareham
and R. C. Travis and S. Merino and E. J. Duell and M.
Rodríguez-Barranco and M. D. Chirlaque and A. Barricarte
and V. Rebours and M.-C. Boutron-Ruault and F. Romana
Mancini and P. Brennan and G. Scelo and J. Manjer and M.
Sund and D. Öhlund and F. Canzian$^*$ and R. Kaaks$^*$},
title = {{CA}19-9 and {A}polipoprotein-{A}2 isoforms as detection
markers for pancreatic cancer - a prospective evaluation.},
journal = {International journal of cancer},
volume = {144},
number = {8},
issn = {0020-7136},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2018-01558},
pages = {1877-1887},
year = {2019},
abstract = {Recently, we identified unique processing patterns of
apolipoprotein A2 (ApoA2) in patients with pancreatic
cancer. This study provides a first prospective evaluation
of an ApoA2 isoform ('ApoA2-ATQ/AT'), alone and in
combination with carbohydrate antigen 19-9 (CA19-9), as an
early detection biomarker for pancreatic cancer. We
performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in
156 patients with pancreatic cancer and 217 matched controls
within the European EPIC cohort, using plasma samples
collected up to 60 months prior to diagnosis. The detection
discrimination statistics were calculated for risk scores by
strata of lag-time. For CA19-9, in univariate marker
analyses, C-statistics to distinguish future pancreatic
cancer patients from cancer-free individuals were 0.80 for
plasma taken ≤6 months before diagnosis, and 0.71 for
>6-18 months; for ApoA2-ATQ/AT, C-statistics were 0.62, and
0.65, respectively. Joint models based on ApoA2-ATQ/AT plus
CA19-9 significantly improved discrimination within >6-18
months (C = 0.74 vs. 0.71 for CA19-9 alone, p = 0.022) and
≤18 months (C = 0.75 vs. 0.74, p = 0.022). At $98\%$
specificity, and for lag times of ≤6, >6-18 or ≤18
months, sensitivities were $57\%,$ $36\%$ and $43\%$ for
CA19-9 combined with ApoA2-ATQ/AT, respectively, vs. $50\%,$
$29\%$ and $36\%$ for CA19-9 alone. Compared to CA19-9
alone, the combination of CA19-9 and ApoA2-ATQ/AT may
improve detection of pancreatic cancer up to 18 months prior
to diagnosis under usual care, and may provide a useful
first measure for pancreatic cancer detection prior to
imaging. This article is protected by copyright. All rights
reserved.},
cin = {C020 / C055},
ddc = {610},
cid = {I:(DE-He78)C020-20160331 / I:(DE-He78)C055-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30259989},
doi = {10.1002/ijc.31900},
url = {https://inrepo02.dkfz.de/record/137681},
}